Skip to main content
placeholder image

Long term effects of olanzapine and betahistine on serotonin 5-HT2A receptor binding in the rat brain

Conference Paper


Abstract


  • Olanzapine is widely used in treating multiple domains of schizophrenia

    symptoms through its binding profiles to various neurotransmitter

    receptors including 5-HT2A receptors (5-HT2AR). Our previous studies

    have shown that 2 weeks co-treatment of betahistine (a H1R agonist

    and H3R antagonist) could reduce obesity induced by olanzapine. This

    study aimed to investigate whether long term co-treatment of olanzapine

    and betahistine affects 5-HT2AR bindings. Methods: Female Sprague-

    Dawley rats were administered under 4 conditions (n=12): (1) Rats were

    treated with vehicle (control) during whole experimental period; (2) Cotreatment

    group (O+B): 5 weeks olanzapine treatment (1 mg/kg, t.i.d.),

    followed by 6 weeks co-administration of olanzapine with betahistine

    (9.6 mg/kg, t.i.d.); (3) olanzapine only (1 mg/kg, t.i.d.) treatment during

    weeks 7-11; (4) betahistine only (9.6 mg/kg, t.i.d.) treatment during weeks

    7-11. Density of 5-HT2AR were measured using [³H]ketanserin. Results:

    Compared to the controls, olanzapine significantly decreased 5-HT2AR

    bindings in accumbens shell and substantia nigra (SN) (p<0.001), as

    well as prefrontal cortex and cingulated cortex (p<0.05). Similar binding

    density changes in these nuclei were also observed in the O+B cotreatment

    group. However, betahistine reduced 5-HT2AR bindings only in

    SN (p<0.001). Conclusion: Co-treatment of olanzapine and betahistine

    had similar effects as sole olanzapine treatment on 5-HT2AR binding.

    These results suggest betahistine co-treatment would be a suitable

    combination therapy to reduce olanzapine-induced weight gain sideeffects

    without affecting 5-HT2A receptors in the brain regions involved

    in treating schizophrenia symptoms.

Publication Date


  • 2013

Citation


  • Lian, J., Huang, X. -F. & Deng, C. (2013). Long term effects of olanzapine and betahistine on serotonin 5-HT2A receptor binding in the rat brain. 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants (pp. 171-171). Australia: ANS.

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/910

Start Page


  • 171

End Page


  • 171

Place Of Publication


  • Australia

Abstract


  • Olanzapine is widely used in treating multiple domains of schizophrenia

    symptoms through its binding profiles to various neurotransmitter

    receptors including 5-HT2A receptors (5-HT2AR). Our previous studies

    have shown that 2 weeks co-treatment of betahistine (a H1R agonist

    and H3R antagonist) could reduce obesity induced by olanzapine. This

    study aimed to investigate whether long term co-treatment of olanzapine

    and betahistine affects 5-HT2AR bindings. Methods: Female Sprague-

    Dawley rats were administered under 4 conditions (n=12): (1) Rats were

    treated with vehicle (control) during whole experimental period; (2) Cotreatment

    group (O+B): 5 weeks olanzapine treatment (1 mg/kg, t.i.d.),

    followed by 6 weeks co-administration of olanzapine with betahistine

    (9.6 mg/kg, t.i.d.); (3) olanzapine only (1 mg/kg, t.i.d.) treatment during

    weeks 7-11; (4) betahistine only (9.6 mg/kg, t.i.d.) treatment during weeks

    7-11. Density of 5-HT2AR were measured using [³H]ketanserin. Results:

    Compared to the controls, olanzapine significantly decreased 5-HT2AR

    bindings in accumbens shell and substantia nigra (SN) (p<0.001), as

    well as prefrontal cortex and cingulated cortex (p<0.05). Similar binding

    density changes in these nuclei were also observed in the O+B cotreatment

    group. However, betahistine reduced 5-HT2AR bindings only in

    SN (p<0.001). Conclusion: Co-treatment of olanzapine and betahistine

    had similar effects as sole olanzapine treatment on 5-HT2AR binding.

    These results suggest betahistine co-treatment would be a suitable

    combination therapy to reduce olanzapine-induced weight gain sideeffects

    without affecting 5-HT2A receptors in the brain regions involved

    in treating schizophrenia symptoms.

Publication Date


  • 2013

Citation


  • Lian, J., Huang, X. -F. & Deng, C. (2013). Long term effects of olanzapine and betahistine on serotonin 5-HT2A receptor binding in the rat brain. 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants (pp. 171-171). Australia: ANS.

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/910

Start Page


  • 171

End Page


  • 171

Place Of Publication


  • Australia